Pfizer details mixed Phase 3 data for Lyme disease vaccine
- Pfizer and Valneva presented fuller results from their Phase 3 Lyme disease vaccine study on Thursday, with outcomes described as mixed.
- One of the two analyses reportedly came close to, but fell short of, its target.
- The vaccine's commercial prospects are described as uncertain pending the next steps.
💡 Points
A near-miss on one of two analyses is a weak footing for a first-in-class Lyme vaccine, and it hands regulators room to ask hard questions. Pfizer carries the commercial risk alongside Valneva, so the filing path and label breadth now matter more than the headline efficacy. Details are thin, so treat any launch timing as unsettled.